Connect with us

INDUSTRIAL HEMP

Axim Biotechnologies Inc (OTCMKTS:AXIM) Gets New U.S. Patent Allowance For CBD Ophthalmic Solutions For Conjunctivitis And Glaucoma Treatment

Published

on

Axim Biotechnologies Inc

Axim Biotechnologies Inc (OTCMKTS:AXIM) reported that the USPTO has issued a Notice of Allowance for a patent that claims the application of an ophthalmic solution comprising CBDs for the treatment of symptomatic relief of conjunctival inflammation and glaucoma. A Notice of Allowance is given after the USPTO makes a decision that a patent can be given from AXIM’s patent application, filed in December 2015.

The details

Axim reported on March 21, 2017 that it kept the services of Ora®, Inc., an international Contract Research Organization, to perform the firm’s product development in dry eye syndrome and glaucoma using CBD-based therapeutics through its AX-1606 and AX-1603 clinical plans.

George E. Anastassov, MD, DDS, the CEO of Axim, reported that as they move forward in their product advancement and clinical studies for dry eye and glaucoma, this patent permitted by the USPTO is important for them to be successful in seeking improved and new CBD-based treatment alternatives for these highly-prevalent ophthalmic ailments with considerable unmet medical needs.

In 2016, international spending on glaucoma management stood at $6 billion, so they are thrilled about the prospect that this new patent gives them to advance new treatments with unique mechanisms of action that will lower the hazard of progression of visual field loss.

Axim Biotechnologies is mainly into the research, development and manufacturing of cannabis-based cosmetic, pharmaceutical and nutraceutical offerings. Its main offerings include CanChew+®, which is a CBD-based chewing gum, CanChew+ 50®, having 50 mg of CBD underway clinical studies in people with MedChew Rx® and IBS, a combination Cannabinoid/THC gum that will pass clinical trials for the treatment of spasticity and pain linked with multiple sclerosis.

The company showcases a number of offerings advanced or in developmental phase for prevention and/or treatment of multiple conditions and indications. It prioritizes the well-being of their consumers while embracing a robust fiscal strategy.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement

Symbol        Alert        High        Gain

 

  VBIO          $0.67       $4.10      500%

  IMLFF        $0.11       $0.57      400%

  CMXC        $0.25       $0.45      80%

  REPCF       $0.54       $0.79      48%

 

Get Your Latest Winner Delivered to Your Inbox!

FREE

For The Next 48 Hours

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement